Which has stronger earnings and valuation, HAE or AORT?

Haemonetics has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 3.62 $97.31M $2.04 52.09 Artivion $441.33M 2.81 $9.77M -$0.07 N/A

Is HAE or AORT more profitable?

Haemonetics has a net margin of 7.12% compared to Artivion's net margin of -0.67%. Haemonetics' return on equity of 27.55% beat Artivion's return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.12% 27.55% 9.65% Artivion -0.67% 6.07% 2.93%

Does the media prefer HAE or AORT?

In the previous week, Artivion had 2 more articles in the media than Haemonetics. MarketBeat recorded 6 mentions for Artivion and 4 mentions for Haemonetics. Haemonetics' average media sentiment score of 0.68 beat Artivion's score of 0.55 indicating that Haemonetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Artivion 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, AORT or LIVN?

Artivion has higher earnings, but lower revenue than LivaNova. Artivion is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artivion $441.33M 2.81 $9.77M -$0.07 N/A LivaNova $1.39B 3.15 -$242.47M $3.38 23.51

Is AORT or LIVN more profitable?

LivaNova has a net margin of 12.82% compared to Artivion's net margin of -0.67%. LivaNova's return on equity of 16.35% beat Artivion's return on equity. Company Net Margins Return on Equity Return on Assets Artivion -0.67% 6.07% 2.93% LivaNova 12.82% 16.35% 7.76%

Does the media favor AORT or LIVN?

In the previous week, LivaNova had 5 more articles in the media than Artivion. MarketBeat recorded 11 mentions for LivaNova and 6 mentions for Artivion. LivaNova's average media sentiment score of 0.59 beat Artivion's score of 0.55 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ITGR or AORT?

Integer has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.85B 2.31 $102.81M $3.66 34.48 Artivion $441.33M 2.81 $9.77M -$0.07 N/A

Is ITGR or AORT more profitable?

Integer has a net margin of 6.97% compared to Artivion's net margin of -0.67%. Integer's return on equity of 12.79% beat Artivion's return on equity. Company Net Margins Return on Equity Return on Assets Integer 6.97% 12.79% 6.48% Artivion -0.67% 6.07% 2.93%

Does the media prefer ITGR or AORT?

In the previous week, Integer had 3 more articles in the media than Artivion. MarketBeat recorded 9 mentions for Integer and 6 mentions for Artivion. Artivion's average media sentiment score of 0.55 beat Integer's score of 0.44 indicating that Artivion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integer 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Artivion 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, AORT or PLSE?

Artivion has higher revenue and earnings than Pulse Biosciences. Artivion is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artivion $441.33M 2.81 $9.77M -$0.07 N/A Pulse Biosciences $350K 10,915.41 -$72.78M -$1.18 N/A

Does the media refer more to AORT or PLSE?

In the previous week, Pulse Biosciences had 6 more articles in the media than Artivion. MarketBeat recorded 12 mentions for Pulse Biosciences and 6 mentions for Artivion. Pulse Biosciences' average media sentiment score of 0.95 beat Artivion's score of 0.55 indicating that Pulse Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulse Biosciences 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IRTC or AORT?

In the previous week, Artivion had 2 more articles in the media than iRhythm Technologies. MarketBeat recorded 6 mentions for Artivion and 4 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.68 beat Artivion's score of 0.55 indicating that iRhythm Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Artivion 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Artivion (AORT) Competitors

$25.42 +0.45 (+1.80%)

Closing price 09/15/2026 03:59 PM Eastern

Extended Trading

$25.39 -0.03 (-0.11%)

As of 09/15/2026 07:30 PM Eastern

Compare

AORT vs. HAE, LIVN, ITGR, PLSE, and IRTC

Should you buy Artivion stock or one of its competitors? Artivion's main competitors and comparable companies include Haemonetics (HAE), LivaNova (LIVN), Integer (ITGR), Pulse Biosciences (PLSE), and iRhythm Technologies (IRTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Artivion compare to Haemonetics?

Haemonetics (NYSE:HAE) and Artivion (NYSE:AORT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Haemonetics has a net margin of 7.12% compared to Artivion's net margin of -0.67%. Haemonetics' return on equity of 27.55% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.12%	27.55%	9.65%
Artivion	-0.67%	6.07%	2.93%

Haemonetics currently has a consensus target price of $99.78, suggesting a potential downside of 6.10%. Artivion has a consensus target price of $44.83, suggesting a potential upside of 76.38%. Given Artivion's stronger consensus rating and higher possible upside, analysts plainly believe Artivion is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

99.7% of Haemonetics shares are held by institutional investors. Comparatively, 86.4% of Artivion shares are held by institutional investors. 2.1% of Haemonetics shares are held by company insiders. Comparatively, 6.3% of Artivion shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Haemonetics has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	3.62	$97.31M	$2.04	52.09
Artivion	$441.33M	2.81	$9.77M	-$0.07	N/A

In the previous week, Artivion had 2 more articles in the media than Haemonetics. MarketBeat recorded 6 mentions for Artivion and 4 mentions for Haemonetics. Haemonetics' average media sentiment score of 0.68 beat Artivion's score of 0.55 indicating that Haemonetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Artivion	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Haemonetics has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Artivion has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market.

Summary

Haemonetics beats Artivion on 11 of the 17 factors compared between the two stocks.

How does Artivion compare to LivaNova?

Artivion (NYSE:AORT) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Artivion has higher earnings, but lower revenue than LivaNova. Artivion is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.81	$9.77M	-$0.07	N/A
LivaNova	$1.39B	3.15	-$242.47M	$3.38	23.51

86.4% of Artivion shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 6.3% of Artivion shares are owned by insiders. Comparatively, 0.4% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Artivion presently has a consensus target price of $44.83, suggesting a potential upside of 76.38%. LivaNova has a consensus target price of $84.13, suggesting a potential upside of 5.86%. Given Artivion's stronger consensus rating and higher possible upside, equities research analysts plainly believe Artivion is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55

In the previous week, LivaNova had 5 more articles in the media than Artivion. MarketBeat recorded 11 mentions for LivaNova and 6 mentions for Artivion. LivaNova's average media sentiment score of 0.59 beat Artivion's score of 0.55 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LivaNova has a net margin of 12.82% compared to Artivion's net margin of -0.67%. LivaNova's return on equity of 16.35% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	-0.67%	6.07%	2.93%
LivaNova	12.82%	16.35%	7.76%

Artivion has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Summary

LivaNova beats Artivion on 10 of the 16 factors compared between the two stocks.

How does Artivion compare to Integer?

Integer (NYSE:ITGR) and Artivion (NYSE:AORT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Integer has a net margin of 6.97% compared to Artivion's net margin of -0.67%. Integer's return on equity of 12.79% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	6.97%	12.79%	6.48%
Artivion	-0.67%	6.07%	2.93%

Integer has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Artivion has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market.

Integer presently has a consensus price target of $109.86, suggesting a potential downside of 12.95%. Artivion has a consensus price target of $44.83, suggesting a potential upside of 76.38%. Given Artivion's stronger consensus rating and higher probable upside, analysts clearly believe Artivion is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

99.3% of Integer shares are held by institutional investors. Comparatively, 86.4% of Artivion shares are held by institutional investors. 1.1% of Integer shares are held by insiders. Comparatively, 6.3% of Artivion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Integer has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	2.31	$102.81M	$3.66	34.48
Artivion	$441.33M	2.81	$9.77M	-$0.07	N/A

In the previous week, Integer had 3 more articles in the media than Artivion. MarketBeat recorded 9 mentions for Integer and 6 mentions for Artivion. Artivion's average media sentiment score of 0.55 beat Integer's score of 0.44 indicating that Artivion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Artivion	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Integer beats Artivion on 9 of the 16 factors compared between the two stocks.

How does Artivion compare to Pulse Biosciences?

Artivion (NYSE:AORT) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

In the previous week, Pulse Biosciences had 6 more articles in the media than Artivion. MarketBeat recorded 12 mentions for Pulse Biosciences and 6 mentions for Artivion. Pulse Biosciences' average media sentiment score of 0.95 beat Artivion's score of 0.55 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulse Biosciences	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.4% of Artivion shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 6.3% of Artivion shares are held by insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Artivion has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market.

Artivion has a net margin of -0.67% compared to Pulse Biosciences' net margin of -6,755.78%. Artivion's return on equity of 6.07% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	-0.67%	6.07%	2.93%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

Artivion currently has a consensus price target of $44.83, indicating a potential upside of 76.38%. Pulse Biosciences has a consensus price target of $45.25, indicating a potential downside of 18.03%. Given Artivion's higher possible upside, equities analysts plainly believe Artivion is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Artivion has higher revenue and earnings than Pulse Biosciences. Artivion is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.81	$9.77M	-$0.07	N/A
Pulse Biosciences	$350K	10,915.41	-$72.78M	-$1.18	N/A

Summary

Artivion beats Pulse Biosciences on 9 of the 17 factors compared between the two stocks.

How does Artivion compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Artivion (NYSE:AORT) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Artivion has a net margin of -0.67% compared to iRhythm Technologies' net margin of -1.69%. iRhythm Technologies' return on equity of 10.11% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-1.69%	10.11%	1.53%
Artivion	-0.67%	6.07%	2.93%

iRhythm Technologies has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market. Comparatively, Artivion has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market.

Artivion has lower revenue, but higher earnings than iRhythm Technologies. Artivion is trading at a lower price-to-earnings ratio than iRhythm Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	4.94	-$44.55M	-$0.43	N/A
Artivion	$441.33M	2.81	$9.77M	-$0.07	N/A

In the previous week, Artivion had 2 more articles in the media than iRhythm Technologies. MarketBeat recorded 6 mentions for Artivion and 4 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.68 beat Artivion's score of 0.55 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Artivion	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.4% of Artivion shares are owned by institutional investors. 1.0% of iRhythm Technologies shares are owned by insiders. Comparatively, 6.3% of Artivion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

iRhythm Technologies presently has a consensus price target of $179.93, indicating a potential upside of 60.82%. Artivion has a consensus price target of $44.83, indicating a potential upside of 76.38%. Given Artivion's higher probable upside, analysts plainly believe Artivion is more favorable than iRhythm Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

iRhythm Technologies beats Artivion on 9 of the 17 factors compared between the two stocks.

Get Artivion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AORT vs. The Competition

Export

Metric	Artivion	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$1.22B	$5.54B	$7.20B	$23.25B
Dividend Yield	N/A	1.79%	2.57%	3.58%
P/E Ratio	-363.08	25.08	272.86	28.40
Price / Sales	2.81	72.21	701.69	20.30
Price / Cash	22.66	32.78	77.71	34.34
Price / Book	2.69	5.99	10.37	4.69
Net Income	$9.77M	$150.13M	$3.49B	$1.07B
7 Day Performance	0.86%	-1.19%	-0.76%	-1.48%
1 Month Performance	-13.00%	-3.80%	-0.39%	-4.27%
1 Year Performance	-35.70%	8.43%	18.93%	8.97%

Artivion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AORT Artivion	3.4583 of 5 stars	$25.42 +1.8%	$44.83 +76.4%	-36.0%	$1.22B	$441.33M	N/A	1,800
HAE Haemonetics	1.7905 of 5 stars	$106.16 +3.4%	$99.78 -6.0%	+106.8%	$4.67B	$1.33B	52.04	3,009	Positive News
LIVN LivaNova	2.4947 of 5 stars	$80.63 +3.1%	$84.13 +4.3%	+43.4%	$4.31B	$1.39B	23.86	3,300	Insider Trade
ITGR Integer	2.5507 of 5 stars	$126.16 +0.1%	$109.86 -12.9%	+26.1%	$4.28B	$1.85B	34.47	11,000
PLSE Pulse Biosciences	1.8423 of 5 stars	$54.21 +2.1%	$45.25 -16.5%	+250.7%	$3.68B	$350K	N/A	116

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AORT) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artivion (AORT) Competitors

AORT vs. HAE, LIVN, ITGR, PLSE, and IRTC

How does Artivion compare to Haemonetics?

Summary

How does Artivion compare to LivaNova?

Summary

How does Artivion compare to Integer?

Summary

How does Artivion compare to Pulse Biosciences?

Summary

How does Artivion compare to iRhythm Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AORT vs. The Competition

Artivion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artivion (AORT) Competitors

AORT vs. HAE, LIVN, ITGR, PLSE, and IRTC

How does Artivion compare to Haemonetics?

Is HAE or AORT more profitable?

Do analysts rate HAE or AORT?

Do institutionals & insiders believe in HAE or AORT?

Which has stronger earnings and valuation, HAE or AORT?

Does the media prefer HAE or AORT?

Which has more volatility and risk, HAE or AORT?

Summary

How does Artivion compare to LivaNova?

Which has preferable earnings and valuation, AORT or LIVN?

Do institutionals and insiders hold more shares of AORT or LIVN?

Do analysts rate AORT or LIVN?

Does the media favor AORT or LIVN?

Is AORT or LIVN more profitable?

Which has more volatility & risk, AORT or LIVN?

Summary

How does Artivion compare to Integer?

Is ITGR or AORT more profitable?

Which has more risk and volatility, ITGR or AORT?

Do analysts rate ITGR or AORT?

Do institutionals & insiders have more ownership in ITGR or AORT?

Which has higher valuation and earnings, ITGR or AORT?

Does the media prefer ITGR or AORT?

Summary

How does Artivion compare to Pulse Biosciences?

Does the media refer more to AORT or PLSE?

Do insiders and institutionals have more ownership in AORT or PLSE?

Which has more volatility & risk, AORT or PLSE?

Is AORT or PLSE more profitable?

Do analysts recommend AORT or PLSE?

Which has preferable earnings & valuation, AORT or PLSE?

Summary

How does Artivion compare to iRhythm Technologies?

Is IRTC or AORT more profitable?

Which has more risk and volatility, IRTC or AORT?

Which has higher valuation & earnings, IRTC or AORT?

Does the media prefer IRTC or AORT?

Do institutionals and insiders have more ownership in IRTC or AORT?

Do analysts prefer IRTC or AORT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AORT vs. The Competition

Artivion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools